Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the antitumor activity (response rate, time to
tumor progression, survival) and safety of docetaxel in combination with talabostat in
patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior
platinum-containing regimen.